Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 1/2010

01-03-2010

Oncocytes, Oxyphils, Hürthle, and Askanazy Cells: Morphological and Molecular Features Of Oncocytic Thyroid Nodules

Authors: Ozgur Mete, Sylvia L. Asa

Published in: Endocrine Pathology | Issue 1/2010

Login to get access

Abstract

Our understanding of oncocytic change in thyroid nodules is evaluated in light of the recent progress in understanding the mitochondrial DNA, its mutations, and somatic mutations that affect mitochondrial function. These changes are largely unrelated to the genetic events that result in proliferation and neoplastic transformation of thyroid follicular epithelial cells. The criteria for diagnosing lesions that are composed predominantly of oncocytic cells are the same as those applied to follicular lesions that do not contain oncocytic cells, including follicular variant papillary carcinomas, based on nuclear morphology, immunohistochemical profiles, and molecular markers.
Literature
1.
Hürthle K. Beitrage zur Kenntiss der Secretionsvorgangs in der Schilddruse. Arch Gesamte Physiol 56:1–44, 1894.CrossRef
2.
Askanazy M. Patologisch anatomische Beitrage zur Kenntiss des Morbus Basedowii, insbesondere uber die dabei auftretende Muskelerkrankung. Dtsch Arch Klin Med 61:118–86, 1898.
3.
Chang A, Harawi SJ. Oncocytes, oncocytosis, and oncocytic tumors. Pathol Annu 27:263–304, 1992.PubMed
4.
Nappi O, Ferrara G, Wick MR. Neoplasms composed of eosinophilic polygonal cells: an overview with consideration of different cytomorphologic patterns. Semin Diagn Pathol 16:82–90, 1999.PubMed
5.
Mete O, Asa SL. Aldosterone-producing adrenal cortical adenoma with oncocytic change and cytoplasmic eosinophilic globular inclusions. Endocr Pathol 20:182–5, 2009.CrossRefPubMed
6.
7.
8.
Boerner SL, Asa SL. Biopsy interpretation of the thyroid. Philadelphia: Lippincott Williams & Wilkins, 2010.
9.
Mete O, Kilicaslan I, Gulluoglu MG, Uysal V. Can renal oncocytoma be differentiated from its renal mimics? The utility of anti-mitochondrial, caveolin 1, CD63 and cytokeratin 14 antibodies in the differential diagnosis. Virchows Arch 447:938–46, 2005.CrossRefPubMed
10.
Tickoo SK, Amin MB, Linden MD, Lee MW, Zarboo RJ. Antimitochondrial antibody (113-1) in the differential diagnosis of granular renal cell tumors. Am J Surg Pathol 21:922–30, 1997.CrossRefPubMed
11.
12.
Slack JM. Metaplasia and transdifferentiation: from pure biology to the clinic. Nat Rev Mol Cell Biol 8:369, 2007.CrossRefPubMed
13.
14.
Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 266:19–42, 2009.CrossRefPubMed
15.
Schägger H, Pfeiffer K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. EMBO J 19:1777–83, 2000.CrossRefPubMed
16.
Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu Rev Biochem 54:1015–69, 1985.CrossRefPubMed
17.
Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, Ceroni AR, Curcio F, Carelli V, Rugolo M, Tallini G, Romeo G. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA104:9001–6, 2007.CrossRefPubMed
18.
Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 66:6087–96, 2006.CrossRefPubMed
19.
Máximo V, Sobrinho-Simões M. Mitochondrial DNA ‘common’ deletion in Hürthle cell lesions of the thyroid. J Pathol 192:561–2, 2000.CrossRefPubMed
20.
Máximo V, Sobrinho-Simões M. Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch 437:107–15, 2000.CrossRefPubMed
21.
Rogounovitch T, Saenko V, Yamashita S. Mitochondrial DNA and human thyroid diseases. Endocr J 51:265–77, 2004.CrossRefPubMed
22.
Máximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, Amaro T, Barbosa AP, Preto A, Harach HR, Williams D, Sobrinho-Simões M. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hürthle cell) tumours of the thyroid. Br J Cancer 92:1892–8, 2005.CrossRefPubMed
23.
24.
Harach HR, Lesueur F, Amati P, Brown A, Canzian F, Kraimps JL, Levillain P, Menet E, Romeo G, Bonneau D. Histology of familial thyroid tumours linked to a gene mapping to chromosome 19p13.2. J Pathol 189:387–93, 1999.CrossRefPubMed
25.
Sheu SY, Handke S, Bröcker-Preuss M, Görges R, Frey UH, Ensinger C, Ofner D, Farid NR, Siffert W, Schmid KW. The C allele of the GNB3 C825T polymorphism of the G protein beta3-subunit is associated with an increased risk for the development of oncocytic thyroid tumours. J Pathol 211:60–6, 2007.CrossRefPubMed
26.
Bonora E, Evangelisti C, Bonichon F, Tallini G, Romeo G. Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br J Cancer 95:1529–36, 2006.CrossRefPubMed
27.
Jacques C, Fontaine JF, Franc B, Mirebeau-Prunier D, Triau S, Savagner F, Malthiery Y. Death-associated protein 3 is overexpressed in human thyroid oncocytic tumours. Br J Cancer 101:132–8, 2009.CrossRefPubMed
28.
DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press, 2004.
29.
Montone KT, Baloch ZW, LiVolsi VA. The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 8:1241–50, 2008.
30.
Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest 79:547–55, 1999.PubMed
31.
Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6:409–16, 1996.CrossRefPubMed
32.
Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21:3226–35, 2003.CrossRefPubMed
33.
Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21(Suppl 2):S37–43, 2008.
34.
Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292–306, 2006.CrossRefPubMed
35.
Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86:2187–90, 2001.CrossRefPubMed
36.
Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 446:589–95, 2005.CrossRefPubMed
37.
McLeod MK, Thompson NW, Hudson JL, Gaglio JA, Lloyd RV, Harness JK, Nishiyama R, Cheung PS. Flow cytometric measurements of nuclear DNA and ploidy analysis in Hürthle cell neoplasms of the thyroid. Arch Surg 123:849–54, 1988.PubMed
38.
Ryan JJ, Hay ID, Grant CS, Rainwater LM, Farrow GM, Goellner JR. Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid. World J Surg 12:482–7, 1988.CrossRefPubMed
39.
Galera-Davidson H, Bibbo M, Bartels PH, Dytch HE, Puls JH, Wied GL. Correlation between automated DNA ploidy measurements of Hürthle-cell tumors and their histopathologic and clinical features. Anal Quant Cytol Histol 8:158–67, 1986.PubMed
40.
Bronner MP, Clevenger CV, Edmonds PR, Lowell DM, McFarland MM, LiVolsi VA. Flow cytometric analysis of DNA content in Hürthle cell adenomas and carcinomas of the thyroid. Am J Clin Pathol 89:764–9, 1988.PubMed
41.
Máximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simões M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol 160:1857–65, 2002.PubMed
42.
Bronner MP, LiVolsi VA. Oxyphilic (Askenasy/Hürthle cell) tumors of the thyroid. Microscopic features predict biologic behavior. Surg Pathol 1:137–50, 1988.
43.
Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336–40, 2004.CrossRefPubMed
44.
Apel RL, Ezzat S, Bapat BV, Pan N, LiVolsi VA, Asa SL. Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol 4:113–21, 1995.CrossRefPubMed
45.
Aeschimann S, Kopp PA, Kimura ET, Zbaeren J, Tobler A, Fey MF, Studer H. Morphological and functional polymorphism within clonal thyroid nodules. J Clin Endocrinol Metab 77:846–51, 1993.CrossRefPubMed
46.
Kopp P, Kimura ET, Aeschimann S, Oestreicher M, Tobler A, Fey MF, Studer H. Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab 79:134–9, 1994.CrossRefPubMed
47.
Rosai J, Kuhn E, Carcangiu ML. Pitfalls in thyroid tumour pathology. Histopathology 49:107–20, 2006.CrossRefPubMed
48.
LiVolsi VA. Hashimoto’s thyroiditis: is the epithelium premalignant? International Congress Series 1299:281–8, 2007.CrossRef
49.
Rosai J. Papillary thyroid carcinoma: a root-and-branch rethink. Am J Clin Pathol 130:683–6, 2008.CrossRefPubMed
50.
Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H, Tallini G. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91:2414–23, 2006.CrossRefPubMed
51.
Sheils OM, O’eary JJ, Uhlmann V, Lättich K, Sweeney EC. ret/PTC-1 Activation in Hashimoto Thyroiditis. Int J Surg Pathol 8:185–9, 2000.CrossRefPubMed
52.
LiVolsi VA. Surgical Pathology of the thyroid, Vol 5. Philadelphia: WB Saunders, 1990.
53.
Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, Wenig BM. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 130:736–44, 2008.CrossRefPubMed
54.
Baloch ZW, LiVolsi VA. Our approach to follicular-patterned lesions of the thyroid. J Clin Pathol 60:244–50, 2007.CrossRefPubMed
55.
Serra S, Asa SL. Controversies in thyroid pathology: the diagnosis of follicular neoplasms. Endocr Pathol 19:156–65, 2008.CrossRefPubMed
56.
Baloch ZW, Martin S, Livolsi VA. Granular cell tumor of the thyroid: a case report. Int J Surg Pathol 13:291–4, 2005.CrossRefPubMed
57.
58.
Mete O, Asa SL. Composite medullary and papillary thyroid carcinoma in a patient with MEN 2B: case report and review of C-cell lesions of the thyroid. Pathology Case Reviews 14:208–13, 2009
59.
Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr Pathol 16:295–309, 2005.CrossRefPubMed
60.
Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 132:359–72, 2008.PubMed
61.
Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14:338–42, 2001.CrossRefPubMed
62.
Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer 18:2637–41, 1998.
63.
Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58:3015–20, 1998.PubMed
64.
Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475–84, 1999.CrossRefPubMed
65.
Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10:668–74, 1997.PubMed
66.
Kato Y, Nakagouri T, Konishi M, Takahashi S, Gotoda N, Hasebe T, Kinosita T. Intraductal oncocytic papillary neoplasm of the pancreas with strong accumulation on FDG-PET. Hepatogastroenterology 55:900–2, 2008.PubMed
67.
Fukunaga N, Fujioka A, Tanaka K, Toyama R. Oncocytic hepatocellular carcinoma with numerous globular hyaline bodies. Pathol Int 46:286–91, 1996.CrossRefPubMed
68.
Hoang MP, Ayala AG, Albores-Saavedra J. Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol 15:973–8, 2002.CrossRefPubMed
Metadata
Title
Oncocytes, Oxyphils, Hürthle, and Askanazy Cells: Morphological and Molecular Features Of Oncocytic Thyroid Nodules
Authors
Ozgur Mete
Sylvia L. Asa
Publication date
01-03-2010
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 1/2010
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-009-9102-2

Other articles of this Issue 1/2010

Endocrine Pathology 1/2010 Go to the issue

EditorialNotes

Letter to the Editor

OriginalPaper

Pituitary Adenomas that Show a Faint GH-Immunoreactivity but Lack Fibrous Body: Pit-1 Adenoma with Endocrinologically Low Activity

OriginalPaper

Poorly Differentiated Thyroid Carcinoma: 5 Years after the 2004 WHO Classification of Endocrine Tumours

OriginalPaper

Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues

Letter

Anti-Cytokeratin CAM 5.2 is Specific for K8 and to a Lesser Extent for the Closely Related K7, but Shows no Reactivity with K18 or K19

OriginalPaper

Determination of Cell Proliferation Using Mcm2 Antigen and Evaluation of Apoptosis and TGF-β1 Expression in GH-secreting or Clinically Nonfunctioning Pituitary Adenomas
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits